Viva Biotech sells 24% stake in CRO business Viva Shanghai for $150m

Viva Biotech sells 24% stake in CRO business Viva Shanghai for $150m

Viva Biotech Holdings Group has announced the fundraising of nearly $150 million by transferring about 24% of its equity interest in Viva Shanghai, its chief entity for contract research organization (CRO) business, to Temasek, HighLight Capital (HLC), and True Light. The transaction has additionally resulted in a profit of around $60 million for the publicly […]

AstraZeneca acquires oral PCSK9 inhibitors from Dogma Therapeutics

AstraZeneca acquires oral PCSK9 inhibitors from Dogma Therapeutics

Pharma giant AstraZeneca has signed a deal to acquire a preclinical oral PCSK9 inhibitor asset from Dogma Therapeutics, a portfolio company of Viva Biotech. The financial terms of the deal were not disclosed. AstraZeneca intends to take the PCSK9 inhibitor program into clinical trials in 2021 for dyslipidemia and also familial hypercholesterolemia. People having dyslipidemia, […]